Search PubMed⌕ Search

Biomedical subjects

C R Westley

Publications and source records attributed to C R Westley.

8 recordsLinked to original sources
PubMed1997

Mugwort and sage (Artemisia) pollen cross-reactivity: ELISA inhibition and immunoblot evaluation.

BACKGROUND: Plants of the genus Artemisia are a source of fall allergic symptoms, particularly in the western United States. Studies have characterized the allergens in one of the major species (A. vulgaris) but currently there are no cross-reactivity data on the major United States species. OBJECTIVE: The purpose of this study was to investigate the in vitro cross-reactivity among nine Artemisia species: A. frigida, A. annua, A. biennis, A. filifolia, A. tridentata, A. californica, A. gnaphalodes, A. ludoviciana, and A. vulgaris. METHODS: The cross-reactivity was demonstrated with the use of enzyme-linked immunosorbent assay (ELISA) inhibitions and immunoblotting techniques utilizing a serum pool from patients allergic to Artemisia species. RESULTS: The enzyme-linked immunosorbent assay inhibitions revealed strong cross-reactivity among all nine species with A. biennis and A. tridentata being two of the strongest inhibitors. The polyacrylamide gel electrophoresis showed a great deal of similarity in the bands among the nine species. The nitrocellulose blots showed similar IgE binding patterns among the Artemisia species with strong inhibition among all nine extracts. CONCLUSIONS: These data all demonstrate very strong in vitro cross-reactivity among the nine Artemisia species studied. Such data have significant clinical relevance, suggesting that a single Artemisia species may be sufficient for allergy skin testing and formulation of immunotherapy extracts.

Antibodies, Anti-Idiotypic↗
PubMed1978

Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study.

Racemic epinephrine has been advocated for the treatment of croup, but controlled studies have not proved it more effective than saline. Twenty patients (aged 4 months to 5 years) hospitalized with acute croup and persistent inspiratory stridor at rest were randomly assigned to one of two treatment groups: saline or racemic epinephrine, both nebulized and delivered by intermittent positive pressure breathing. Clinical scores were significantly improved (P less than .01) at ten and 30 minutes following the treatment with racemic epinephrine but not at 120 minutes. Racemic epinephrine was significantly more effective than saline at 10 (P less than .01) and 30 minutes (P less than .05) but not at 120 minutes after the treatment. We conclude that nebulized racemic epinephrine is effective treatment for the acute signs of croup.

Acute Disease↗
PubMedDate not supplied

Cost effectiveness of an allergy consultation in the management of asthma.

In a large Denver HMO, a retrospective study of asthma management was reviewed. Seventy moderate to severe asthmatic patients' charts were reviewed through April 1994. All patients admitted to the study had to be followed for at least 1 year by a primary care physician before the allergy evaluation (AE) and for at least one year of followup (F/U) after the AE. All patients had at least two acute care (ER) visits and/or one hospitalization before the AE. All primary care, AE, and F/U were done by staff physicians in the Kaiser Permanente system. The findings included 1) Forty-five percent decrease (308 to 169) in the number of sick care office visits (P = 0.0001); 2) fifty-five percent decrease (266 to 118) in acute care visits (P = 0.0001); 3) sixty-seven percent decrease (34 to 11) in the number of hospitalizations after the AE (P = 0.001); 4) average hospital days before AE were four days and after AE, 2.5 days; 5) estimated cost saving of $145,500, or $2,100 per patient.

Acute Disease↗